| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.1 | 0.0 |
| Net income | -7.9 | -4.6 |
| EPS (diluted, $ a share) | $-0.31 | $-0.45 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NYSE: SER. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Serina Therapeutics, Inc.: key numbers
- Share price
- $1.42Close, Nov 16
- Market cap
- $37.7M
- Shares outstanding
- 26.57MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Serina Therapeutics, Inc.
All →Serina Therapeutics Financial Results
Serina Therapeutics reported third quarter 2026 financial results and provided a clinical update on its SER-252 program for Parkinson's disease. The company has advanced to Cohort 2 of its registrational study following a positive safety review, with topline single-ascending-dose data expected in the first half of 2027.
“We are excited about the achievement of important clinical milestones for SER-252 in Parkinson's disease, advancing from the initial evaluation of our lowest-dose cohort into the next stage of dose escalation. Importantly, the blinded pharmacokinetic observations from Cohort 1 showed the sustained drug exposure SER-252 was designed to achieve, and the independent Safety Monitoring Committee recommended proceeding with continued development.”
Steve Ledger, Chief Executive Officer
Serina Therapeutics Other 8-K Filing
Serina Therapeutics filed a Certificate of Elimination with the State of Delaware to remove the Series A Convertible Preferred Stock designation from its charter. All previously issued shares of Series A Preferred Stock have been converted into common stock, and the eliminated shares have returned to the status of authorized but unissued preferred stock.